Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%.
The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis.
In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures.
This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study.
54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency.
The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved.
The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed.
The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly.
On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028.
In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow.
Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs.
Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday.
Read Next:Photo via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
MSA Safety (NYSE:MSA) Beats Expectations in Strong Q2
Safety equipment manufacturer MSA Safety (NYSE:MSA) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 2.5% year on year to $474.1 million. Its non-GAAP profit of $1.93 per share was 10% above analysts' consensus estimates. Is now the time to buy MSA Safety? Find out in our full research report. MSA Safety (MSA) Q2 CY2025 Highlights: Revenue: $474.1 million vs analyst estimates of $447.8 million (2.5% year-on-year growth, 5.9% beat) Adjusted EPS: $1.93 vs analyst estimates of $1.76 (10% beat) Adjusted EBITDA: $116.5 million vs analyst estimates of $105 million (24.6% margin, 10.9% beat) The company maintained its low-single-digit full-year organic sales growth outlook for 2025, while acknowledging ongoing risk due to macroeconomic factors Operating Margin: 18.1%, down from 23.5% in the same quarter last year Free Cash Flow Margin: 8%, similar to the same quarter last year Market Capitalization: $6.89 billion "Our second quarter financial performance demonstrates our team's commitment to our Accelerate strategy and creating long-term value for our stakeholders," said Steve Blanco, MSA Safety President and CEO. Company Overview Founded in 1914 as Mine Safety Appliances to protect coal miners from dangerous gases, MSA Safety (NYSE:MSA) designs and manufactures advanced safety products that protect workers and facilities across industries including fire service, energy, construction, and manufacturing. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. With $1.83 billion in revenue over the past 12 months, MSA Safety is a mid-sized business services company, which sometimes brings disadvantages compared to larger competitors benefiting from better economies of scale. On the bright side, it can still flex high growth rates because it's working from a smaller revenue base. As you can see below, MSA Safety's sales grew at a decent 5.8% compounded annual growth rate over the last five years. This shows its offerings generated slightly more demand than the average business services company, a useful starting point for our analysis. Long-term growth is the most important, but within business services, a half-decade historical view may miss new innovations or demand cycles. MSA Safety's recent performance shows its demand has slowed as its annualized revenue growth of 4.6% over the last two years was below its five-year trend. This quarter, MSA Safety reported modest year-on-year revenue growth of 2.5% but beat Wall Street's estimates by 5.9%. Looking ahead, sell-side analysts expect revenue to grow 4.5% over the next 12 months, similar to its two-year rate. This projection doesn't excite us and suggests its newer products and services will not accelerate its top-line performance yet. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating Margin MSA Safety has been a well-oiled machine over the last five years. It demonstrated elite profitability for a business services business, boasting an average operating margin of 20.7%. Analyzing the trend in its profitability, MSA Safety's operating margin rose by 4.6 percentage points over the last five years, as its sales growth gave it operating leverage. In Q2, MSA Safety generated an operating margin profit margin of 18.1%, down 5.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. MSA Safety's EPS grew at a solid 10.2% compounded annual growth rate over the last five years, higher than its 5.8% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into MSA Safety's earnings to better understand the drivers of its performance. As we mentioned earlier, MSA Safety's operating margin declined this quarter but expanded by 4.6 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business. For MSA Safety, its two-year annual EPS growth of 9.3% is similar to its five-year trend, implying stable earnings. In Q2, MSA Safety reported adjusted EPS at $1.93, down from $2.01 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 10%. Over the next 12 months, Wall Street expects MSA Safety's full-year EPS of $7.69 to grow 8.6%. Key Takeaways from MSA Safety's Q2 Results We were impressed by how significantly MSA Safety blew past analysts' revenue expectations this quarter. We were also glad its EPS outperformed Wall Street's estimates. The company maintained its low-single-digit full-year organic sales growth outlook for 2025, while acknowledging ongoing risk due to macroeconomic factors. Zooming out, we think this quarter featured some important positives but the commentary around guidance adds some uncertainty to the picture, something investors don't love. Shares traded down 1.4% to $175 immediately following the results. Is MSA Safety an attractive investment opportunity right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Tesla Awards Musk $29 Billion in Shares as 2018 Pay Battle Continues
Tesla (TSLA, Financials) granted CEO Elon Musk an interim award of 96 million shares, valued at about $29 billion, while his disputed $56 billion 2018 compensation package remains under review by the Delaware Supreme Court. The award will vest in two years if Musk stays as CEO or in another top role. It will be forfeited if the court clears the 2018 package, which was previously struck down by a Delaware judge as improperly approved. Shareholders re?approved that plan in June 2024. The move follows Tesla's weak quarterly results, with sales falling for a second straight quarter and automotive revenue down 16%. Musk warned of possible rough quarters ahead as EV tax credit cuts loom. The company will hold another shareholder meeting in November. This article first appeared on GuruFocus.
Yahoo
2 minutes ago
- Yahoo
Here's What Traders Expect AMD Stock To Do After Earnings
Advanced Micro Devices (AMD) is set to report second-quarter results after the closing bell on Tuesday, with traders anticipating a sizable move from the chipmaker's stock. Current options pricing suggests traders expect the stock could move more than 7% by the end of this week, from Monday's close near $177. A move of that scale would push the stock just over $190, nearing its record high in March of last year. At the low end, the stock could drop to about $163. The shares have gained more than 45% in 2025 so far. AMD shares rose close to 2% the day after the company's first-quarter report, while they fell 6% and 10%, respectively, the days after the two previous reports. In May, the company beat estimates and gave a revenue forecast with a midpoint above the analyst consensus. The chipmaker is widely expected to report rising sales, but falling profits for the second quarter, after AMD warned in May that it would likely take a hit from tighter restrictions on chip exports to China. Wall Street analysts surveyed by Visible Alpha are divided on the stock, but lean more bullish than bearish, after AMD reportedly said it plans to resume exports of its MI308 chips to China, once authorized by U.S. authorities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
